bivalent HPV vaccine

Phase 3Vaccine

ZZagazig University

bivalent HPV vaccine is one of 4 small molecule programs targeting HPV Vaccine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HPV VaccineRecruiting

HPV VaccinationRecruiting

HPV VaccinePhase 2

Recruiting

HPV VaccinationPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in HPV Vaccine

#DrugCompanyPhaseTrials

HPV Vaccine

SShanghai Zerun Biotechnology Co.,Ltd

Phase 3

1 2

Nonavalent HPV Vaccine

XXiamen University

Phase 3

1 3

bivalent HPV vaccine

ZZagazig University

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Human Papilloma Virus

NCT02834637

Q4 2027

Phase 3Active, not recruiting

Papilloma

NCT04537156

Q4 2029

Post-ApprovalRecruiting

HPV Vaccination

NCT07281677

Clinical

Trials by Indication[1]

HPV Vaccine1 trial

Candida Antigen and Bivalent HPV Vaccine in the Treatment of Multiple Warts

Recruiting·ZZagazig University·Phase 2·NCT05291845·162 enrolled

HPV Vaccination1 trial

Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years

Recruiting·ZZhejiang Provincial Center for Disease Control and Prevention·Phase 4·NCT07281677·400 enrolled

Papilloma1 trial

Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Active, not recruiting·XXiamen University·Phase 3·NCT04537156·9,327 enrolled

Human Papilloma Virus1 trial

A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

Active, not recruiting·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT02834637·930 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for bivalent HPV vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — bivalent HPV vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for bivalent HPV vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zagazig University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: ZZagazig University

bivalent HPV vaccine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2029

Trials by Indication[1]

HPV Vaccine1 trial

HPV Vaccination1 trial

Papilloma1 trial

Human Papilloma Virus1 trial

References

Drug Info

Quick Facts

Related News